By the Top Tier Newswire AI Desk · July 24, 2026 at 12:12 AM ET · reviewed against 4 wire stories
ARGENX SE ADR (ARGX) is up +8.56% in the latest session. Our newswire has captured 4 stories on ARGX across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 69/100).
ARGX stock rose 8.56 percent to $924.60 on Tuesday as strong second-quarter performance and positive analyst sentiment fueled investor optimism. The biotech firm reported $1.5 billion in global product net sales for VYVGART, a 60 percent year-over-year increase, and announced two key pipeline readouts expected before year-end. Recent analyst upgrades and a favorable earnings report also contributed to the stock’s upward momentum.
What Happened
Armenx delivered a robust second quarter, with VYVGART sales expanding to all serotypes of generalized myasthenia gravis. The company’s second-quarter revenue grew 60 percent year-over-year and 17 percent quarter-over-quarter. Earnings per share of $7.32 exceeded estimates of $6.24, while total sales of $1.542 billion beat expectations of $1.442 billion. The company also confirmed that two registrational study readouts are expected before the end of 2026, reinforcing its growth trajectory.
Analysts have responded positively, with Citigroup raising its price target to $1182 and RBC Capital lifting its target to $945. Piper Sandler also increased its target to $820 from $750. These upgrades, combined with the strong earnings report, have driven renewed investor interest.
What To Watch
Armenx has a scheduled earnings call on July 23, 2026, where management will provide further details on the second-quarter business update. Investors should monitor coverage breadth and analyst commentary in the coming days for additional insight into the company’s momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
ARGX · Jul 24 session (5-min) · -0.69% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 4 stories · 69/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
6d agoYahoo TopBULLISH 73Product/PR
argenx VYVGART Sales Rise 60% as Pipeline Readouts Approach
argenx delivered $1. 5 billion in second-quarter VYVGART product sales and entered the second half with two registrational study readouts expected before year-end.
6d agoMarketChameleonBULLISH 73Earnings
argenx Delivers Strong Q2 with VYVGART Expansion and 60% Revenue Growth—Pipeline Readouts on the Horizon
July 23, 2026
argenx posted a robust second quarter in 2026, seeing 60% year-over-year growth in product sales and expanding the reach of its lead product, VYVGART, to all serotypes of generalized myasthenia gravis. With multiple late-stage readouts expected in the coming quarters, the company’s financials and pipeline progress support its Vision 2030 goals.
7d agoReutersBULLISH 67Earnings
Argenx's Vyvgart sales jump in second quarter
7d agoBusiness InsiderBULLISH 63Earnings
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
Strong second quarter performance with $1.5 billion in global product net sales, representing 60% year-over-year growth and 17% quarter-over-quarter growth Successfully launched...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →